Gemfibrozil in Late Preterm and Term Neonates with Moderate Jaundice: A Randomized Controlled Trial.
Indian Pediatr
;
2009 Dec; 46(12): 1063-1069
Artículo
en Inglés
| IMSEAR
| ID: sea-168359
ABSTRACT
Objective:
To determine, if oral Gemfibrozil is effective in decreasing the duration of phototherapy by at least 24 hours in neonates >34 weeks gestation with nonhemolytic jaundice, as compared to placebo.Design:
Double blind placebo controlled randomized controlled trial.Setting:
Tertiary care neonatal unit in north India.Subjects:
Ninety seven neonates >34 weeks gestation with non-hemolytic jaundice within first 7 days of life requiring phototherapy. Intervention Two doses of Gemfibrozil (60 mg/kg/dose) or placebo, 12 hours apart. Babies were treated with single surface special blue light phototherapy. Serum total bilirubin (STB) was measured 8 hourly. Phototherapy was stopped if two consecutive STB values were below phototherapy zone. Primary outcomemeasure:
Duration of phototherapy.Results:
The median (IQR) duration of phototherapy was 40 (30, 60) hours in Gemfibrozil and 36 (19, 55) hours in the placebo group (P=0.13). The peak STB levels were 16.8 ± 2.7 mg/dL and 16.3 ± 2.3 mg/dL in Gemfibrozil and placebo groups, respectively. No side effect of the drug or placebo was noticed.Conclusion:
Two doses of gemfibrozil (60mg/kg/dose) given 12 hours apart were not able to reduce the duration of phototherapy, or peak bilirubin level in babies > 34 weeks gestation with non-hemolytic jaundice in the first week of life. Gemfibrozil was not associated with any side effects.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Tipo de estudio:
Ensayo Clínico Controlado
Idioma:
Inglés
Revista:
Indian Pediatr
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS